Astellas Pharma’s ZIMURA Market size expansion of Several Folds by 2030

Astellas Pharma’s ZIMURA Market size expansion of Several Folds by 2030
The recently published in-depth report on ZIMURA (Astellas Pharma) provides insights into the drug market landscape and market forecast of ZIMURA upto 2030.

[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on ZIMURA (Astellas Pharma) providing insights into the drug market landscape and market forecast of ZIMURA upto 2030. The report, titled “ZIMURA Market Size, Forecast, and Emerging Insight – 2030” is now available for review and analysis.


Are you interested in finding out the projected market size of ZIMURA in 2030? ZIMURA Market Forecast


The ZIMURA Market Report offers projected sales forecasts for ZIMURA for indications until 2030, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of  competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.


Astellas Pharma’s ZIMURA is serving as a beacon of hope for the patients suffering from the Geographic Atrophy. 


Izervay is administered through a monthly eye injection for a maximum of 12 months. The FDA granted breakthrough therapy designation in January under the name Zimura. The manufacturing is conducted by Astellas Pharma Inc.


The report extensively covers the details and developments related to ZIMURA, capturing important highlights on developmental pipeline, regulatory status and special designations of ZIMURA, route of administration, safety and efficacy details.


ZIMURA Market Assessment

This report provides a detailed market assessment of ZIMURA for Geographic Atrophy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.


ZIMURA Clinical Assessment

The report provides the clinical trials information of ZIMURA for Geographic Atrophy covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related. 


Do you know your drug’s competitive positioning against ZIMURA? ZIMURA Drugs Insights


ZIMURA Competitive Landscape 

The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the ZIMURA.


ZIMURA Market Size in the US

A dedicated section of the report focuses on the expected market size of ZIMURA for the United States. DelveInsight’s analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.


What is a ZIMURA Prescribed for?

Avacincaptad pegol (ACP), also recognized as Zimura, has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA). This designation is attributed to the drug’s potential to decelerate the advancement of geographic atrophy, an advanced and severe manifestation of dry age-related macular degeneration that poses the risk of causing irreversible vision loss.


Key Highlights of ZIMURA: 

  • The report contains forecasted sales of ZIMURA  for indication till 2032.
  • Comprehensive coverage of the late-stage emerging therapies for Geographic Atrophy.
  • The report also features the qualitative and quantitative analysis with analysts as well as KOL views for ZIMURA in Geographic Atrophy.


Stay ahead in competition by leveraging insights on ZIMURA market Report: Download ZIMURA Market Report


Why you should buy ZIMURA Market Report:

  • The report provides future market assessments for ZIMURA for Geographic Atrophy in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts’ views, detailed overview of market competitors, and short analysis of other emerging therapies in Ulcerative Colitis.
  • Leading ZIMURA for Geographic Atrophy forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ZIMURA 
  • Discover the competitive landscape of ZIMURA through 7MM
  • Get a Thorough Analysis of the ZIMURA Development pipeline, Safety & Efficacy of the ZIMURA, and ROA
  • Thorough ZIMURA market forecast will help understand how drug is competing with other emerging ZIMURA
  • Get analysis of the ZIMURA clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
  • Drug Market forecasts are calculated after taking into consideration KOL viewpoints


Related Reports By DelveInsight:

Geographic Atrophy Pipeline 

DelveInsight’s, Geographic Atrophy Pipeline Insight, 2024 report provides comprehensive insights about 23+ companies and 25+ pipeline drugs in Ulcerative Colitis (UC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 


Top Services Offered By DelveInsight:

Explore success with our case study on R&D, Manufacturing & Commercial Capabilities. Uncover insights for strategic growth in the industry.


About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States